Another viral vector vaccines MG1-MAGEA3 (NCT02879760), based on genetically engineered Maraba MG1 rhabdovirus to carry cancer cell antigen MAGEA3, has been combined with an anti-PD1 monoclonal antibody for NSCLC treatment. Here, MAGEA3 is linked to non-small cell lung carcinoma.